[go: up one dir, main page]

WO2013032206A1 - Composition orale à libération prolongée contenant du chlorhydrate d'itopride, et procédé de préparation associé - Google Patents

Composition orale à libération prolongée contenant du chlorhydrate d'itopride, et procédé de préparation associé Download PDF

Info

Publication number
WO2013032206A1
WO2013032206A1 PCT/KR2012/006850 KR2012006850W WO2013032206A1 WO 2013032206 A1 WO2013032206 A1 WO 2013032206A1 KR 2012006850 W KR2012006850 W KR 2012006850W WO 2013032206 A1 WO2013032206 A1 WO 2013032206A1
Authority
WO
WIPO (PCT)
Prior art keywords
fitness
sustained
release
weight
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/006850
Other languages
English (en)
Korean (ko)
Inventor
최연웅
민병구
조상민
기도형
박영민
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea United Pharm Inc
Original Assignee
Korea United Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea United Pharm Inc filed Critical Korea United Pharm Inc
Publication of WO2013032206A1 publication Critical patent/WO2013032206A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a method for producing a sustained-release tablet containing itopride hydrochloride as an active substance, specifically, the convenience of taking and compared to conventional commercial preparations to be extended three times a day so that it can be taken once a day Provide sustained-release tablets to improve medication compliance.
  • Itopride hydrochloride (N-[[4- (2-dimethylaminoethoxy) phenyl] methyl] -3,4-dimethoxybenzamide) inhibits acetylcholine esterase and antagonizes dopamine D2 receptor
  • the acetylcholine promotes gastrointestinal peristalsis, and is a drug used for digestive symptoms such as bloating, epigastric pain, anorexia, chest pain, and vomiting due to functional dyspepsia.
  • This drug is suitable for long-term use because peripheral dopamine D2 antagonism shows little side effects such as gynecomastia and milk secretion, which is a side effect of gastrointestinal function improving agents such as domperidone.
  • Itopride Hydrochloride (N-[[4- (2-Dimethylaminoethoxy) phenyl] methyl] -3,4-dimethoxybenzamide) has an action time of 30 minutes oral administration and reaches a peak blood concentration of about 0.5 ⁇ 1.5 hours, duration is about 12 hours. It is known that about 80% of etopriide is excreted in the urine upon oral administration, and the excretion rate (half life) is about 6 hours.
  • Itopride formulations Patients who take long-term use of Itopride formulations have not been developed as a dosage form that can be taken once a day, even though they have to take long-term doses due to frequent symptoms caused by stress due to the characteristics of patients with poor digestion. Inconvenience in medication guidance and medication compliance may result.
  • the present invention can help to prevent the loss of medication or worsening of symptoms by forgetting to take the patient by the sustained release of the dosage form of itopride hydrochloride three times a day.
  • the technical problem to be achieved by the present invention is characterized by a matrix tablet with an active ingredient of itopride hydrochloride, the drug that was administered three times a day 50mg each day by 150mg once a day dose of about 150 hours without dissolution variation
  • the present invention provides sustained-release tablets containing itopride hydrochloride that effectively release the drug to sustain it, thereby increasing the therapeutic effect and simplifying the formulation therapy of patients with gastrointestinal diseases, thereby improving patient convenience and dosage compliance.
  • the release controlling polymer is hydroxypropylmethylcellulose. It is characterized in that the sustained release of itopride hydrochloride.
  • the weight ratio of the hydroxypropyl methyl cellulose is preferably 10% to 45% of the total weight.
  • the disintegrant is Croscarcamellose Sodium, Sodium Starch Glycolate, Pregelatinized Starch (Starch 1500 or Premojel) , Microcrystalline cellulose, crospovidone (cross-linked povidone), polyvinylpyrrolidone (PVP, Povidone), hydroxypropylcellulose (low substituted), alginic acid (alginic) acid, calcium and sodium salts of Carboxymethylcellulose, fumed silica, colloidal silica, guar gum, Magnesium aluminum silicate, methylcellulose, One or two selected from the group consisting of powdered cellulose, starch and sodium alginate And more thereof, wherein the filler is one or a mixture of two or more selected from microcrystalline cellulose, gyeoljil silicic acid anhydride, the group consisting of before the gelling starch and lactose and the lubricant is magnesium stearate (magnesium stearate), si
  • the dissolution rate of the sustained-release tablets is 10 to 30% at 1 hour, 55 to 75% at 12 hours and 85% or more at 24 hours.
  • Itopride sustained-release tablet according to the present invention can effectively control the release of etopriide hydrochloride for 24 hours at a rate close to zero order without dissolution deviation, thereby solving the inconvenience of eating three times a day by eating once a day
  • the tablet weight is 450mg per tablet, the patient's medication compliance is high due to the small tablet size, which can prevent the loss of efficacy and the worsening of symptoms.
  • Figure 2 shows the results of the dissolution test (eluate: purified water) of the formulations described in Comparative Examples 1 and 2 and Example 10 of the present invention.
  • Figure 3 shows the results of the wear and tear test of the formulations described in Examples 1 to 10 of the present invention.
  • Figure 4 shows the results of the hardness test of the formulations described in Examples 1 to 10 of the present invention.
  • the present invention is an oral composition formulated with itopride hydrochloride (N-[[4- (2-dimethylaminoethoxy) phenyl] methyl] -3,4-dimethoxybenzamide), which is a very useful drug for treating digestive disorders.
  • itopride hydrochloride N-[[4- (2-dimethylaminoethoxy) phenyl] methyl] -3,4-dimethoxybenzamide
  • the present invention relates to an oral sustained-release composition in which etopride hydrochloride is eluted at a constant rate for 24 hours to give a sufficient therapeutic effect by taking a daily dose, and to reduce the weight of tablets to increase ease of taking.
  • Itopride hydrochloride sustained-release tablet of the present invention has the advantage of slowly releasing the active ingredient at the release rate almost similar to the 0th order with the same biological activity but once a day as compared to the conventionally taken drug three times a day Have
  • composition of the sustained-release tablet according to the present invention is 30% by weight of the pharmacological active ingredient itopride hydrochloride, 45% by weight of hydroxypropylmethylcellulose, 5% by weight of microcrystalline cellulose, 6% by weight of lactose, 5% by weight of low-substituted hydroxypropyl cellulose It is an isopride hydrochloride sustained-release tablet composition containing%, povidone 3% by weight, lubricant 1% by weight.
  • the sustained-release agent should form a hydrogel matrix to effectively control the release of itopride hydrochloride having a very high water solubility, and should have an appropriate viscosity range.
  • the 24 hour release control means that the pH of the patient's body goes through different organs, so the sustained release agent should have little change in viscosity or release pattern with pH.
  • Hydroxypropylmethylcellulose is suitable as a sustained-release base that satisfies the above conditions and has a long dissolution time and is capable of relatively constant dissolution rate control.
  • composition of the present invention when hydroxypropyl cellulose is made into a 2% by weight aqueous solution and the viscosity is measured at 20 ° C., when the viscosity is 80,000 cps or less, the highly soluble diphosphide hydrochloride is effectively released for 24 hours. It is not controllable, and when 120,000 cps or more, hydroxypropyl methyl cellulose having a viscosity in the range of 80,000 cps to 120,000 cps is suitable because the initial gel hydration time is delayed to increase the elution deviation.
  • composition of the present invention when hydroxypropylmethylcellulose is included in less than 10% by weight of the total composition, it is also not possible to effectively control the release of itopride hydrochloride having a very high water solubility for 24 hours, more than 45% by weight When it is enacted, since poor compression and capping problems may occur, it is preferable to include 10 to 45% by weight of the total composition.
  • a binder in order to make tablets desirable.
  • a binder having an appropriate binding force because it is necessary to minimize the amount of excipient added to the tablet.
  • polyvinylpyrrolidone commonly name is povidone and povidone K-30 having a molecular weight of 30 is used
  • the binder is less than 3% by weight.
  • disintegrants are used to absorb moisture to promote initial disintegration of the formulation, to facilitate dissolution of the itopride hydrochloride
  • examples of disintegrants that can be used in the formulation of the present invention are croscarmellose.
  • the disintegrant includes at least one selected from the group consisting of croscarmellose sodium, sodium starch glycolate, pregelatinized starch, microcrystalline cellulose, crospovidone, and commercially available low-substituted hydroxypropylcellulose. Mixtures.
  • the glidants in the present invention are characterized in that one or two or more kinds selected from the group consisting of silicon dioxide, stearic acid and magnesium stearate, and preferably magnesium stearate can be used.
  • the glidant improves the fluidity of the powder to be tableted to increase the filling ability of the tableting machine into the die, and improves the friction between the powders and the punch-die which is the upper part of the powder and the tongue. Reduction to facilitate compression of the tablets.
  • one or more excipients selected from the group consisting of lactose, glucose, mannitol, white sugar, sorbitol, microcrystalline cellulose, calcium phosphate, calcium dihydrogen phosphate, and dextrin may be added in a daily amount and used as described above.
  • Coating bases can be used to prevent the appearance of the active ingredients, sustained-release agents, binders, glidants and to improve the appearance.
  • Additives commonly used in the pharmaceutical art, such as surfactants, stabilizers, preservatives, may also be added.
  • Method for preparing an oral preparation of sustained-release tablet of etopriide comprises the steps of: (1) mixing the topride hydrochloride with microcrystalline cellulose and lactose and hydroxypropylmethylcellulose as a pharmacologically active ingredient; (2) a granulation step of preparing wet sustained-release granules by adding a liquid solvent in which a binder is dissolved to the mixture obtained in the mixing step; (3) milling the ground granules; (4) tableting after mixing the lubricants; (5) It consists of a coating step of coating with a suitable coating base. All of the above steps can be easily formulated using equipments such as mixers, grinders, tablets, etc., which are conventionally used, so that there is no additional equipment cost and can be easily formulated with high productivity. There is this.
  • Example 3 It is the same as Example 1 except the weight of each component is the same as Table 3.
  • Example 4 It is the same as Example 1 except the weight ratio of each component is as Table 4.
  • Example 5 It is the same as Example 1 except the weight ratio of each component is the same as Table 5.
  • Example 6 It is the same as Example 1 except the weight ratio of each component is the same as Table 6.
  • Example 1 It is the same as Example 1 except the weight ratio of each component is the same as Table 9.
  • Example 1 It is the same as Example 1 except the weight ratio of each component is the same as Table 10.
  • Example 1 It is the same as Example 1 except the weight ratio of each component is shown in Table 11.
  • Comparative Examples were prepared with the ingredients and contents shown in Table 12 below. After mixing itopride hydrochloride, lactose, carboxymethyl cellulose, and colloidal silicon dioxide, corn starch solution dissolved in purified water is added, and then granulated and granulated, and dried in a fluidized bed dryer at 50 ° C. for 6 hours. After granulating the obtained granules, the remaining colloidal silicon dioxide and magnesium stearate were mixed and tableted, and then coated with Opadry-OY-C-7000A (trade name of Colorcon, Inc.), Ito containing 50 mg of itopride hydrochloride in one tablet. Fried hydrochloride makes regular tablets. The weight percentages of the components are shown in Table 12.
  • Example 13 It is the same as Example 1 except the viscosity unit of the hydroxypropyl methylcellulose used as a sustained-release base is different.
  • the weight percentages of the components are shown in Table 13.
  • Example 14 It is the same as Example 1 except the viscosity unit of the hydroxypropyl methylcellulose used as a sustained-release base is different.
  • the weight percentages of the components are shown in Table 14.
  • the eluate was collected at the time after the start of the dissolution test, and the absorbed liquid was measured at 266 nm using an ultraviolet-visible absorbance spectrophotometer using an ultraviolet-visible absorption spectrophotometer.
  • Example 1 10.64 ⁇ 0.03 5.49 ⁇ 0.02 10.6 ⁇ 0.25 0.96 451.6 ⁇ 2.3
  • Example 2 10.67 ⁇ 0.02 5.47 ⁇ 0.05 11.2 ⁇ 0.43 0.91 452.1 ⁇ 3.5
  • Example 3 10.71 ⁇ 0.04 5.46 ⁇ 0.04 11.9 ⁇ 0.65 0.85 453.2 ⁇ 4.1
  • Example 4 10.69 ⁇ 0.06 5.47 ⁇ 0.06 12.8 ⁇ 0.47 0.78 449.3 ⁇ 2.3
  • Example 5 10.62 ⁇ 0.04 5.48 ⁇ 0.03 13.2 ⁇ 0.21 0.74 452.4 ⁇ 4.9
  • Example 6 10.65 ⁇ 0.05 5.51 ⁇ 0.06 13.7 ⁇ 0.81 0.65 451.6 ⁇ 5.1
  • Example 7 10.69 ⁇ 0.07 5.45 ⁇ 0.04 14.2 ⁇ 0.36 0.62 453.1 ⁇ 4.8
  • Example 8 10.67 ⁇ 0.03 5.47 ⁇ 0.09 14.9 ⁇ 0.42 0.54 4
  • the stability test of the itopride hydrochloride was carried out under the conditions of 1-4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de préparation d'un comprimé à libération prolongée contenant du chlorhydrate d'itopride comme principe actif, et plus spécifiquement, la présente invention concerne un comprimé à libération prolongée dont la dissolution est prolongée pour permettre l'administration d'une dose par jour, ce qui permet d'améliorer le confort d'administration et l'observance du traitement par comparaison avec des préparations commerciales existantes qui sont à prendre trois fois par jour. Le comprimé à libération prolongée d'itopride selon la présente invention peut contrôler efficacement la libération du chlorhydrate d'itopride avec une vitesse proche de l'ordre zéro pendant 24 heures sans écart de dissolution, donc le problème de la prise de trois doses par jour peut être résolu par la prise d'une seule dose par jour. En outre, étant donné que chaque comprimé pèse 450 mg et est de petite taille, l'observance du traitement par le patient est élevée, ce qui permet d'empêcher toute perte d'efficacité ou toute aggravation des symptômes.
PCT/KR2012/006850 2011-08-31 2012-08-28 Composition orale à libération prolongée contenant du chlorhydrate d'itopride, et procédé de préparation associé Ceased WO2013032206A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0088206 2011-08-31
KR1020110088206A KR20130024644A (ko) 2011-08-31 2011-08-31 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법

Publications (1)

Publication Number Publication Date
WO2013032206A1 true WO2013032206A1 (fr) 2013-03-07

Family

ID=47756583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006850 Ceased WO2013032206A1 (fr) 2011-08-31 2012-08-28 Composition orale à libération prolongée contenant du chlorhydrate d'itopride, et procédé de préparation associé

Country Status (2)

Country Link
KR (1) KR20130024644A (fr)
WO (1) WO2013032206A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106167A (zh) * 2015-09-28 2015-12-02 迪沙药业集团有限公司 一种盐酸伊托必利组合物
CN105267171A (zh) * 2015-10-13 2016-01-27 迪沙药业集团有限公司 盐酸伊托必利组合物
CN111374958A (zh) * 2019-01-01 2020-07-07 珠海润都制药股份有限公司 一种盐酸伊托必利片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018933A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system
US20070160664A1 (en) * 2004-01-06 2007-07-12 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent
KR20110082665A (ko) * 2010-01-12 2011-07-20 삼일제약주식회사 트리메부틴 및 프로키네틱제를 함유하는 안정한 약학 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018933A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system
US20070160664A1 (en) * 2004-01-06 2007-07-12 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent
KR20110082665A (ko) * 2010-01-12 2011-07-20 삼일제약주식회사 트리메부틴 및 프로키네틱제를 함유하는 안정한 약학 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. G. PRAJAPATI ET AL.: "Matrix sustained release tablet of water soluble prokinetic agent: Itopride hydrochloride", E-JOURNAL OF SCIENCE AND TECHNOLOGY, vol. 5, September 2010 (2010-09-01), pages 67 - 75 *
V. MAHAGUNA ET AL.: "Influence of hydroxypropyl methylcellulose polymer on in vitro and in vivo performance of controlled release tablets containing alprazolam", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 56, 2003, pages 461 - 468, XP004470485, DOI: doi:10.1016/S0939-6411(03)00116-4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106167A (zh) * 2015-09-28 2015-12-02 迪沙药业集团有限公司 一种盐酸伊托必利组合物
CN105106167B (zh) * 2015-09-28 2019-07-12 迪沙药业集团有限公司 一种盐酸伊托必利组合物
CN105267171A (zh) * 2015-10-13 2016-01-27 迪沙药业集团有限公司 盐酸伊托必利组合物
CN105267171B (zh) * 2015-10-13 2019-07-12 迪沙药业集团有限公司 盐酸伊托必利组合物
CN111374958A (zh) * 2019-01-01 2020-07-07 珠海润都制药股份有限公司 一种盐酸伊托必利片及其制备方法

Also Published As

Publication number Publication date
KR20130024644A (ko) 2013-03-08

Similar Documents

Publication Publication Date Title
WO2014142616A1 (fr) Préparation à libération prolongée de mosapride pour fournir des effets cliniques pharmacologiques avec une administration une fois par jour
KR100836960B1 (ko) 새로운 나이아신 제어방출형 제제
WO2011053003A2 (fr) Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg
WO2013147462A1 (fr) Composition pharmaceutique comprenant de l'olmésartan médoxomil et de la rosuvastatine ou son sel
WO2013058450A1 (fr) Composition médicale à base d'épérisone stabilisée, et préparation à libération prolongée contenant celle-ci
WO2021194253A1 (fr) Composition de comprimé oral de pomalidomide et son procédé de préparation
WO2011152652A2 (fr) Préparation d'acéclofénac à libération lente présentant un effet clinique pharmacologique optimal lorsqu'elle est administrée une fois par jour
KR101485421B1 (ko) 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법
WO2010071320A2 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
WO2019066555A1 (fr) Composition pharmaceutique comprenant un comprimé sphéroïdal à unités multiples contenant de l'ésoméprazole et un sel de qualité pharmaceutique de celui-ci, et procédé de préparation de la composition pharmaceutique
WO2013032206A1 (fr) Composition orale à libération prolongée contenant du chlorhydrate d'itopride, et procédé de préparation associé
WO2016006862A1 (fr) Préparation solide comprenant de l'alfoscérate de choline et son procédé de préparation
WO2021101295A1 (fr) Composition pharmaceutique orale comprenant un composé carbamate et procédé de préparation de cette composition
WO2012148181A2 (fr) Composition à libération contrôlée de médicaments
WO2023113488A1 (fr) Combinaison pharmaceutique à commodité améliorée à usage interne par réduction de taille pour formulation comprenant de la dapagliflozine et de la sitagliptine et son procédé de préparation
WO2019160243A1 (fr) Composition pharmaceutique à libération prolongée contenant du lacosamide
WO2016137266A2 (fr) Composition pharmaceutique contenant de l'épérisone et du pélubiprofène
WO2013157841A1 (fr) Comprimé à libération prolongée contenant de la lévodropropizine et procédé pour préparer celui-ci
WO2020171404A1 (fr) Composition pharmaceutique
WO2014157852A1 (fr) Composition médicinale à libération prolongée contenant de l'épérisone en tant que principe actif
WO2017116031A1 (fr) Composition pharmaceutique contenant du géfitinib, pouvant être administrée à des patients présentant une intolérance au lactose, et présentant une commodité de dosage améliorée
WO2015056956A1 (fr) Composition pharmaceutique à libération contrôlée à base d'acide propionique
WO2023022520A1 (fr) Composition de comprimé oral de ruxolitinib et son procédé de préparation
WO2022075760A1 (fr) Composition pharmaceutique comprenant de l'aprémilast
WO2024155042A1 (fr) Formulation de mosapride à libération prolongée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12828944

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12828944

Country of ref document: EP

Kind code of ref document: A1